摘要
目的 :检测端粒酶在乳腺组织中的表达 ,探讨其在诊断和预后中的意义。方法 :采用TRAP -ELISA方法 ,对109例乳腺癌、30例正常乳腺组织及囊性增生病、30例乳腺腺纤维瘤和10例乳腺癌前病变进行端粒酶活性检测。结果 :正常乳腺组织及囊性增生病无端粒酶活性 ,乳腺腺纤维瘤有23 33 %端粒酶呈弱表达 ,乳腺癌前病变有4例端粒酶表达。乳腺癌中88 07 %可以检测到端粒酶活性 ,随着临床分期的增加 ,端粒酶阳性率不断上升。其中端粒酶阳性率在临床I期为64 29% ,II期及以上为91 58 % (P<0.05)。端粒酶阳性率在腋淋巴结转移阴性组中为75 56 % ,而转移阳性组中为96 88 % (P<0.01)。端粒酶表达在ER( -)组与ER(+)组间无明显差别。端粒酶表达在PgR( -)为95 08 % ,在PgR( +)组为79 17% (P<0.01)。结论 :正常乳腺组织中无端粒酶表达。从乳腺癌癌前病变至各期乳腺癌中 ,端粒酶表达逐渐上升 ,端粒酶激活可能是乳腺癌形成和发展中的关键步骤 ,可以为乳腺癌诊断提供重要依据 。
To detect the expression of ribonucleoprotein enzyme telomerases ,and explore its significance in diagnosis and prognosis.Methods:Telomerase acti vity was detected in 109 breast cancers,30 normal tissues and fibrocystic lesion s,30 fibroadenomas,and 10 precancerous lesions.Results:Telomerase activity was n ot detected in any 30 normal tissues and fibrocystic lesions,surprisingly low le vels of telomerase activity were detected by 23.33% in fibroadenomas.Among samp les of precancerous lesions,telomerase activity was detected by 40.00%. In PgR( -)and PgR(+)cancers, the activity was 95.08% and 79.17% respectively.Conclus ion:Telomerase reactivity is a hallmark in cancer form and developmet.Telomerase activity is a good biomarker for diagnosis.Since RNA component of telomerase is very shot,it can be used as a favorable target of gene therapy.
出处
《天津医药》
CAS
北大核心
2002年第10期600-602,共3页
Tianjin Medical Journal
